RALEIGH – Kineticos Life Sciences, which launched in 2020 with a fund topping $5 million, is rolling out a second fund and has already pulled in $55 million, according to an SEC filing.
Kineticos wants to raise $100 million and has already secured 17 backers, the filing notes.
To date, Kineticos has made two investments, according to Crunchbase. One was Inceptor Bio earlier this year; the other was Promaxo.
According to its website Kineticos “will focus on large, unmet medical needs in oncology, neurosciences and rare diseases. In oncology, new approaches to solid tumors and ‘off the shelf’ allogeneic cell therapies are immediate priorities. Kineticos will support entrepreneur-scientists and the biotech community through Series A funding.”
At the time of its launch, Kineticos founder and CEO Shailesh Maingi explained the objectives: “Our core mission is to advance life science research by supporting biotech companies in their pursuit of new treatments for patients. Yet, today with the most difficult to treat diseases, such as cancer, advancement is measured in months of increased life expectancy. With the advent and success of new disruptive technologies in life sciences, we believe how medicine is practiced today is fundamentally changing. For the first time, rational scientists, physicians, and entrepreneurs talk about a cure for cancer.”
Inceptor Bio launches advanced manufacturing platform to treat cancers
